Greenhalgh D G, Gamelli R L, Lee M, Delavari M, Lynch J B, Hansbrough J F, Achauer B M, Miller S F, MacPhee M, Bray G L
Shriners Hospitals for Children, Northern California, Sacramento 95817, USA.
J Trauma. 1999 Mar;46(3):433-40. doi: 10.1097/00005373-199903000-00014.
The primary purpose of this multicenter study was to evaluate the safety and potential efficacy of a solvent/detergent-treated commercial fibrin sealant (human) for topical hemostasis in skin grafting.
The study involved a prospective evaluation of changes in viral titers in patients with burns less than 15% after treatment with fibrin sealant (human). Each patient served as his/her own control for an unblinded, randomized comparison of donor site hemostasis and healing. Preoperative serum was obtained to screen for viral titers. At autografting, the recipient site and one of two randomly chosen donor sites were treated with fibrin sealant (human). The use of other hemostatic agents, including epinephrine was prohibited. Each donor site was covered with gauze to collect blood for estimation of the relative amount of bleeding. The healing of the graft and donor sites was observed. Viral titers and wounds were checked monthly for 6 months, and at 9 and 12 months postoperatively.
Viral titers for human immunodeficiency virus; hepatitis A, B, and C; Epstein-Barr virus; and cytomegalovirus were obtained before and after treatment. Of 47 patients, 34 completed the full year of observation. After treatment, there were no seroconversions to any of the aforementioned viruses. Bleeding at the recipient site appeared well controlled with fibrin sealant (human). Although investigators felt that fibrin sealant (human) improved donor site hemostasis, differences in hemoglobin measurements of blood-soaked dressings failed to reach significance. No differences were noted with regard to acceleration of donor site healing, graft take, or scar maturation at the two groups of donor sites. Anecdotally, the maturation of the recipient site appeared to be accelerated.
Fibrin sealant (human) is safe for use during excision and grafting, and its topical hemostatic potential needs to be examined in patients with larger burns. Its role in scar maturation also needs to be investigated.
这项多中心研究的主要目的是评估一种经溶剂/去污剂处理的商用(人源)纤维蛋白密封剂用于皮肤移植局部止血的安全性和潜在疗效。
该研究前瞻性评估了纤维蛋白密封剂(人源)治疗后烧伤面积小于15%的患者病毒滴度的变化。每位患者作为自身对照,进行非盲、随机的供皮区止血和愈合比较。术前采集血清以筛查病毒滴度。在自体移植时,用纤维蛋白密封剂(人源)处理受皮区和两个随机选择的供皮区之一。禁止使用包括肾上腺素在内的其他止血剂。每个供皮区用纱布覆盖以收集血液,用于估计出血的相对量。观察移植区和供皮区的愈合情况。术后6个月内每月检查病毒滴度和伤口情况,并在术后9个月和12个月进行检查。
在治疗前后获取了人类免疫缺陷病毒、甲型、乙型和丙型肝炎病毒、爱泼斯坦-巴尔病毒和巨细胞病毒的病毒滴度。47例患者中,34例完成了全年观察。治疗后,未出现上述任何病毒的血清转化。纤维蛋白密封剂(人源)对受皮区出血的控制效果良好。尽管研究人员认为纤维蛋白密封剂(人源)改善了供皮区止血,但血渍敷料血红蛋白测量值的差异未达到显著水平。两组供皮区在供皮区愈合加速、移植成活率或瘢痕成熟方面未观察到差异。据观察,受皮区的成熟似乎有所加速。
纤维蛋白密封剂(人源)在切除和移植过程中使用是安全的,其局部止血潜力需要在大面积烧伤患者中进行研究。其在瘢痕成熟中的作用也需要进一步研究。